Currently do not support the use of quetiapine

  • Understudied for acute agitation
  • Risk of orthostatic hypotension and sedation
  • Risk of anticholinergic side effects, especially at high doses


12.5–25 mg PO (onset 30–90 minutes)


Mullinax S, Shokraneh F, Wilson MP, Adams CE. Oral medication for agitation of psychiatric origin: a scoping review of randomized controlled trials. J Emerg Med. 2017;53(4):524–529

Currier GW, Trenton AJ, Walsh PG, van Wijngaarden E. A pilot, open-label safety study of quetiapine for treatment of moderate psychotic agitation in the emergency setting. J Psychiatr Pract. 2006;12(4):223–228

Villari V, Rocca P, Fonzo V, Montemagni C, Pandullo P, Bogetto F. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):405–413